Company Overview and News
With seasonal volatility, rising interest rates, uncertainty over a tariff war with China and fast-approaching mid-term elections all on the minds of investors, the best ETFs to buy now are those that invest in defensive areas of the market.
ABT DUKH STZ.B PG D DUK STZ ABT GLD O87 JNJ KO CI PFE UNH NEE
If you’re a market participant looking to re-direct your focus away from international challenges like Saudi Arabia, North Korea, Russia, et. al., you’re in luck: Q3 earnings reports are hitting the tape fast and furious at this hour. We will take this opportunity to summarize a handful of them.
JNJ NFLX MSFT MS
Johnson & Johnson (NYSE: JNJ) reported its third-quarter financial results before the markets opened on Thursday. The company said that it had $2.05 in earnings per share (EPS) and $20.35 billion in revenue. That compared with consensus estimates of $2.03 in EPS and $20.05 billion in revenue, as well as the $1.90 per share and $19.65 billion posted in the same period of last year.
Johnson & Johnson (JNJ - Free Report) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.
MBWM JNJ CTRL UNH
October's top net gain "safer" Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.
AMGN GRFS GILD DGX MCK SNY MDT STE JNJ PRGO NVS ABBV ABBV
2018-10-15 investorplace - 1
Last week’s market collapse made headlines throughout the world. Even my professional associates who aren’t necessarily investment-savvy asked for my thoughts and guidance. After years of robust returns, the thought of a widespread correction is jarring. Nevertheless, you still want to keep your wits about you, as this is an ideal time to consider which stocks to buy.
AMZN ABX T PX JNJ XOM VZ INTC VZA ABX
A late-afternoon bounce in U.S. equities helped lift investors’ spirits, but doubts still linger as key indices hang near their 200-day moving averages and as tech continues to struggle ahead of earnings season. Here are our top stock trades to start the week.
BAC GS SCHW JPM JNJ ATVI
2018-10-15 seekingalpha - 1
The changes that are underway closely mirror the process that alcohol went through after prohibition ended in the 1920s: liquor regained social acceptance and the product proliferated.
STZ.B ACBFF ITYBF TLRY APH WEED RLLRF GWP SMG IMBBY SHOP RRL CRON SF SFN STZ CGC HEIA QBC MFC ACB 0945 JNJ CBD MFC APHQF SFB IMBBF CNNRF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to JNJ / Johnson & Johnson on message board site Silicon Investor.
|JNJ-Super company, Super stock!||JNJ-Super company, Super stock!||JNJ-Super company, Super stock!|
as of ET